

From Art to Science

Dr. Petra Laux Head Global Public and Government Affairs July 2013



"If it would not be about the variability among individuals medicine could well be a science and not an art"


Sir William Osler 1849-1919





2 | From Art to Science | Petra Laux | July 2013 | Geneva | Business Use Only

Health relies on many more components than treating disease



The need: Treatments for old and new diseases

Fighting Invaders



- **Parasites**
- Bacteria
- Viruses

Stopping Deterioration



- Alzheimers
- Arthritis
- Blindness
- Deafness
- Osteoporosis
- Frailty

Beating Bad habits



- **Diabetes**
- CV disease

4 | From Art to Science | Petra Laux | July 2013 | Geneva | Business Use Only

Lung disease

Controlling Hyper actives



Cancer


NOVARTIS

Autoimmune

Historical achievements From pain relief to disease modifying treatments

1900 Pain relief **1920/30** Surviving infections 1950/60 Controlling inflammation Preventing Polio et all 1970/80 Surviving organ loss & cancer 1990 Controlling CV risk 2010 Complex diseases, Less side effect

Innovation enabling environment



Determinants of future R&D results

Advances in science and technology

Wishes and fears of society

Laws and regulations for new technologies

Role of the Pharmaceutical industry in shaping the future



U NOVARTIS



Principles for delivering treatments in the future...












U NOVARTIS

8 | From Art to Science| Petra Laux| July 2013| Geneva| Business Use Only

Looking at diseases/treatments differently *"From where to what"*




U NOVARTIS


9 | From Art to Science | Petra Laux | July 2013 | Geneva | Business Use Only

Targeted Treatments


The right treatment for the right patient at the right time



- Genetics & epigenetics & biom
- Disease pathway
- New mutations



Technology enabled "diagnosis, treatment & monitoring"







Organ Printing






Information overflow



- Genetic Data
- Diagnostic data
- Electronic Health Records
- Behavioral information
- Therapy specificities



The Problem of current drug development: Using Old Approaches to Develop New Drugs

Today



- Rigid
- System centered
- Pen and paper

Tomorrow



- Flexible
- Patient centered
- Digital



How to enable the new paradigm

The Task

- Understanding the underlying mechanisms
- Proving efficacy and safety
 - Individualized treatments
 - Effects 20 years in the future?
- Leveraging scientific possibilities

Rewarding innovation

The Need

- Incentives for academia
- New concepts/laws to test/approve
 - Use of computer models
 - Adaptive trials/Biomarkers
 - Gene modification/therapy; Stem cells
 - Precompetitive collaborations (e.g. IMI)
- Fast adapting regulations
 - Diagnostics, Implants, Devices
 - Access and use of information
- Predictable market
- Alignment on what constitutes value
- Fair & differentiated prices

A four point plan for innovation in Europe

Facilitate	A	Apply		Protect	
Smart & effective regulation	Equal access at highest level aligned with social market economy	Outcomes-bas healthcare systems	ed	Agenda for the knowledge economy	
 Reduce unnecessary bureaucracy and cost burden Improve clarity of procedures Adapt legislation to advancements in science 	 Eliminate access differentials in Europe in line with social market economy Facilitate speedy uptake of innovation with lean procedures 	 Use innovatio improve patien outcomes Total cost/ val outcomes approach to healthcare 	nt	 Protect intellectual property, thus foster future investments Robust trade agenda for stronger industry competitiveness on global markets 	

U NOVARTIS

15 | From Art to Science | Petra Laux | July 2013 | Geneva | Business Use Only

Another opinion on the future: Mikhail Gorbachev



- The future depends on what we do today
- We should not be taken hostage by the current mix of political and economic interests
- Change starts with new ideas and courageous leaders
- Everyone has a role to play







17 | From Art to Science| Petra Laux| July 2013| Geneva| Business Use Only